Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 874054, 10 pages
Research Article

Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study

1Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
3Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
4Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan
5Chang Gung University College of Medicine, Linkou, Taiwan
6Department of Public Health, Chang Gung University, Taoyuan 333, Taiwan
7Pathology Core of the Chang Gung Molecular Medicine Research Center, Taoyuan 333, Taiwan

Received 2 March 2015; Accepted 22 June 2015

Academic Editor: Bryan C. Fuchs

Copyright © 2015 Sum-Fu Chiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The cancer cell secretome has been recognized as a valuable reservoir for identifying novel serum/plasma biomarkers for different cancers, including colorectal cancer (CRC). This study aimed to verify four CRC cell-secreted proteins (tumor-associated calcium signal transducer 2/trophoblast cell surface antigen 2 (TACSTD2/TROP2), tetraspanin-6 (TSPAN6), bone marrow stromal antigen 2 (BST2), and tumor necrosis factor receptor superfamily member 16 (NGFR)) as potential plasma CRC biomarkers. Methods. The study population comprises 152 CRC patients and 152 controls. Target protein levels in plasma and tissue samples were assessed by ELISA and immunohistochemistry, respectively. Results. Among the four candidate proteins examined by ELISA in a small sample set, only BST2 showed significantly elevated plasma levels in CRC patients versus controls. Immunohistochemical analysis revealed the overexpression of BST2 in CRC tissues, and higher BST2 expression levels correlated with poorer 5-year survival (46.47% versus 65.57%; ). Further verification confirmed the elevated plasma BST2 levels in CRC patients (2.35 ± 0.13 ng/mL) versus controls (1.04 ± 0.03 ng/mL) (), with an area under the ROC curve (AUC) being 0.858 comparable to that of CEA (0.867). Conclusion. BST2, a membrane protein selectively detected in CRC cell secretome, may be a novel plasma biomarker and prognosticator for CRC.